Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 6/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035513 | 0.91 | JAK2 (0.42) | EIF2AK4JAK2JAK1JAK3IGF1R | |
| SCHEMBL1995485 | 0.85 | IRAK4 (0.42) | EIF2AK4JAK2JAK1JAK3CYP3A4 | |
| SCHEMBL1997090 | 0.82 | JAK2 (0.40) | EIF2AK4JAK2JAK1JAK3IGF1R | |
| SCHEMBL1996583 | 0.78 | EIF2AK4 (0.60) | EIF2AK4GPR119 | |
| SCHEMBL1994136 | 0.77 | JAK2 (0.42) | EIF2AK4JAK2JAK1JAK3CYP3A4 | |
| SCHEMBL1997645 | 0.73 | EIF2AK4 (0.45) | EIF2AK4JAK2JAK1JAK3 | |
| SCHEMBL1996606 | 0.73 | JAK2 (0.40) | EIF2AK4JAK2JAK1JAK3 | |
| SCHEMBL1994794 | 0.72 | IRAK4 (0.46) | EIF2AK4EGLN2JAK2JAK1JAK3 | |
| SCHEMBL1997369 | 0.72 | IRAK4 (0.46) | EIF2AK4EGLN2JAK2JAK1JAK3 | |
| SCHEMBL1995331 | 0.72 | IRAK4 (0.46) | EIF2AK4EGLN2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | EIF2AK4 211/4885EGLN2 1369/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.